Addex Therapeutics Ltd Cash Flow Conversion Efficiency

Latest as of March 2026: -0.233x

Addex Therapeutics Ltd cash flow conversion efficiency. Based on the latest financial reports, Addex Therapeutics Ltd (ADXN) has a cash flow conversion efficiency ratio of -0.233x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CHF-765.84K ≈ $-968.23K USD) by net assets (CHF3.29 Million ≈ $4.16 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Cash Flow Conversion Efficiency of Addex Therapeutics Ltd (2006–2025)

Cash flow conversion efficiency of Addex Therapeutics Ltd from 2006 to 2025. This chart illustrates how Addex Therapeutics Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. View ADXN stock price for real-time trading data and today's change.

Addex Therapeutics Ltd Cash Flow Conversion Ratio Explained

Addex Therapeutics Ltd cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.

Addex Therapeutics Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Addex Therapeutics Ltd ranked by their cash flow conversion efficiency. Also see market cap of Addex Therapeutics Ltd for the company's overall valuation and market capitalisation.

Company	Cash Flow Conversion Efficiency
Frp Advisory Group Plc LSE:FRP	0.275x
TZ Ltd AU:TZL	0.218x
Classic Minerals Ltd AU:CLZ	0.016x
Octopus Renewables Infra Trust LSE:ORIT	0.039x
Groupe Airwell Société anonyme PA:ALAIR	-0.126x
Euro Menkul Kiymet Yatirim Ortakligi AS IS:EUYO	0.005x
IQE PLC LSE:IQE	0.005x
Aeeris Ltd AU:AER	-0.227x

Annual Cash Flow Conversion Efficiency for Addex Therapeutics Ltd (2006–2025)

The table below shows the annual cash flow conversion efficiency of Addex Therapeutics Ltd from 2006 to 2025. Review Addex Therapeutics Ltd free cash flow generation to assess how much free cash flow the company generates relative to operating cash flow.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	CHF4.76 Million ≈ $6.02 Million	CHF-2.17 Million ≈ $-2.75 Million	-0.456x	+17.85%
2024-12-31	CHF9.67 Million ≈ $12.23 Million	CHF-5.37 Million ≈ $-6.79 Million	-0.556x	+92.04%
2023-12-31	CHF1.15 Million ≈ $1.45 Million	CHF-7.99 Million ≈ $-10.10 Million	-6.977x	-108.55%
2022-12-31	CHF4.91 Million ≈ $6.21 Million	CHF-16.44 Million ≈ $-20.78 Million	-3.346x	-285.22%
2021-12-31	CHF16.93 Million ≈ $21.41 Million	CHF-14.71 Million ≈ $-18.59 Million	-0.869x	-4.18%
2020-12-31	CHF14.61 Million ≈ $18.47 Million	CHF-12.18 Million ≈ $-15.40 Million	-0.834x	-124.41%
2019-12-31	CHF25.52 Million ≈ $32.27 Million	CHF-9.48 Million ≈ $-11.99 Million	-0.372x	-932.20%
2018-12-31	CHF39.24 Million ≈ $49.61 Million	CHF1.75 Million ≈ $2.21 Million	0.045x	+102.81%
2017-12-31	CHF1.34 Million ≈ $1.70 Million	CHF-2.13 Million ≈ $-2.70 Million	-1.590x	+87.10%
2016-12-31	CHF218.59K ≈ $276.36K	CHF-2.69 Million ≈ $-3.41 Million	-12.326x	-680.44%
2015-12-31	CHF1.66 Million ≈ $2.10 Million	CHF-2.63 Million ≈ $-3.32 Million	-1.579x	-105.86%
2014-12-31	CHF2.35 Million ≈ $2.97 Million	CHF-1.80 Million ≈ $-2.28 Million	-0.767x	+85.28%
2013-12-31	CHF3.03 Million ≈ $3.83 Million	CHF-15.78 Million ≈ $-19.95 Million	-5.214x	-188.38%
2012-12-31	CHF16.29 Million ≈ $20.60 Million	CHF-29.45 Million ≈ $-37.24 Million	-1.808x	-130.40%
2011-12-31	CHF33.84 Million ≈ $42.78 Million	CHF-26.55 Million ≈ $-33.57 Million	-0.785x	-61.27%
2010-12-31	CHF64.41 Million ≈ $81.44 Million	CHF-31.34 Million ≈ $-39.62 Million	-0.487x	+4.14%
2009-12-31	CHF77.58 Million ≈ $98.08 Million	CHF-39.38 Million ≈ $-49.78 Million	-0.508x	-239.45%
2008-12-31	CHF118.99 Million ≈ $150.44 Million	CHF-17.79 Million ≈ $-22.49 Million	-0.150x	+36.53%
2007-12-31	CHF140.11 Million ≈ $177.13 Million	CHF-33.00 Million ≈ $-41.73 Million	-0.236x	+49.08%
2006-12-31	CHF42.28 Million ≈ $53.45 Million	CHF-19.56 Million ≈ $-24.73 Million	-0.463x	--

About Addex Therapeutics Ltd

SW:ADXN Switzerland Biotechnology

Market Cap

$4.34 Million

CHF3.43 Million CHF

Market Cap Rank

#29005 Global

#213 in Switzerland

Share Price

CHF0.02

Change (1 day)

+0.00%

52-Week Range

CHF0.02 - CHF0.07

All Time High

CHF3.90